Literature DB >> 20410122

Disrupted transforming growth factor-beta signaling in spinal and bulbar muscular atrophy.

Masahisa Katsuno1, Hiroaki Adachi, Makoto Minamiyama, Masahiro Waza, Hideki Doi, Naohide Kondo, Hiroyuki Mizoguchi, Atsumi Nitta, Kiyofumi Yamada, Haruhiko Banno, Keisuke Suzuki, Fumiaki Tanaka, Gen Sobue.   

Abstract

Spinal and bulbar muscular atrophy (SBMA) is a late-onset lower motor neuron disease caused by the expansion of a trinucleotide CAG repeat, which encodes a polyglutamine tract in androgen receptor (AR). Although it is commonly held that the pathogenic polyglutamine proteins accumulate in neurons and thereby induce transcriptional dysregulation, the downstream molecular events have remained elusive. Here, we examined whether TGF-beta signaling is dysregulated in SBMA. Nuclear translocation of phosphorylated Smad2/3, a key step in TGF-beta signaling, is suppressed in the spinal motor neurons of male transgenic mice carrying the mutant human AR. A similar finding was also observed in the motor neurons, but not in Purkinje cells, of SBMA patients. The pathogenic AR, the causative protein of SBMA, inhibits the transcription of TGF-beta receptor type II (TbetaRII) via abnormal interactions with NF-Y and p300/CBP-associated factor. Furthermore, overexpression of TbetaRII dampens polyglutamine-induced cytotoxicity in a neuroblastoma cell line expressing the pathogenic AR. The present study thus indicates that disruption of TGF-beta due to the transcriptional dysregulation of TbetaRII is associated with polyglutamine-induced motor neuron damage in SBMA.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20410122      PMCID: PMC6632356          DOI: 10.1523/JNEUROSCI.0388-10.2010

Source DB:  PubMed          Journal:  J Neurosci        ISSN: 0270-6474            Impact factor:   6.167


  38 in total

1.  Viral delivery of miR-196a ameliorates the SBMA phenotype via the silencing of CELF2.

Authors:  Yu Miyazaki; Hiroaki Adachi; Masahisa Katsuno; Makoto Minamiyama; Yue-Mei Jiang; Zhe Huang; Hideki Doi; Shinjiro Matsumoto; Naohide Kondo; Madoka Iida; Genki Tohnai; Fumiaki Tanaka; Shin-ichi Muramatsu; Gen Sobue
Journal:  Nat Med       Date:  2012-07       Impact factor: 53.440

Review 2.  NF-Y (CBF) regulation in specific cell types and mouse models.

Authors:  Sankar N Maity
Journal:  Biochim Biophys Acta Gene Regul Mech       Date:  2016-11-02       Impact factor: 4.490

Review 3.  Spinal and Bulbar Muscular Atrophy.

Authors:  Christopher Grunseich; Kenneth H Fischbeck
Journal:  Neurol Clin       Date:  2015-09-08       Impact factor: 3.806

4.  Naratriptan mitigates CGRP1-associated motor neuron degeneration caused by an expanded polyglutamine repeat tract.

Authors:  Makoto Minamiyama; Masahisa Katsuno; Hiroaki Adachi; Hideki Doi; Naohide Kondo; Madoka Iida; Shinsuke Ishigaki; Yusuke Fujioka; Shinjiro Matsumoto; Yu Miyazaki; Fumiaki Tanaka; Hiroki Kurihara; Gen Sobue
Journal:  Nat Med       Date:  2012-09-30       Impact factor: 53.440

5.  Neuronal expression of TATA box-binding protein containing expanded polyglutamine in knock-in mice reduces chaperone protein response by impairing the function of nuclear factor-Y transcription factor.

Authors:  Shanshan Huang; Joseph J Ling; Su Yang; Xiao-Jiang Li; Shihua Li
Journal:  Brain       Date:  2011-07       Impact factor: 13.501

Review 6.  Modulation of Molecular Chaperones in Huntington's Disease and Other Polyglutamine Disorders.

Authors:  Sara D Reis; Brígida R Pinho; Jorge M A Oliveira
Journal:  Mol Neurobiol       Date:  2016-09-22       Impact factor: 5.590

Review 7.  Pathogenic mechanisms and therapeutic strategies in spinobulbar muscular atrophy.

Authors:  Jason P Chua; Andrew P Lieberman
Journal:  CNS Neurol Disord Drug Targets       Date:  2013-12       Impact factor: 4.388

8.  Microarray analysis of gene expression by skeletal muscle of three mouse models of Kennedy disease/spinal bulbar muscular atrophy.

Authors:  Kaiguo Mo; Zak Razak; Pengcheng Rao; Zhigang Yu; Hiroaki Adachi; Masahisa Katsuno; Gen Sobue; Andrew P Lieberman; J Timothy Westwood; D Ashley Monks
Journal:  PLoS One       Date:  2010-09-23       Impact factor: 3.240

9.  Muscle expression of mutant androgen receptor accounts for systemic and motor neuron disease phenotypes in spinal and bulbar muscular atrophy.

Authors:  Constanza J Cortes; Shuo-Chien Ling; Ling T Guo; Gene Hung; Taiji Tsunemi; Linda Ly; Seiya Tokunaga; Edith Lopez; Bryce L Sopher; C Frank Bennett; G Diane Shelton; Don W Cleveland; Albert R La Spada
Journal:  Neuron       Date:  2014-04-16       Impact factor: 17.173

Review 10.  Polyglutamine androgen receptor-mediated neuromuscular disease.

Authors:  Elisa Giorgetti; Andrew P Lieberman
Journal:  Cell Mol Life Sci       Date:  2016-05-17       Impact factor: 9.261

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.